HomeAgenda

Project cooperationUpdated on 8 September 2025

Engineered EV Platform: Multivalent Infectious-Disease Vaccines & application for Drug Delivery System (DDS)(改変型EVによる多価感染症ワクチンとDDSへの展開)

About

**EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.

**Our engineered EV platform enables a multivalent intranasal vaccine (Influenza A/B + SARS-CoV-2).

Design: multi-antigen loading with proprietary antigen shielding allowing adult intranasal use.

Efficacy: rapid (~Day 8) induction with >6-month durability; variant-resilient and boostable.

Safety/UX: low reactogenicity, non-invasive/painless.

Stability: refrigerated and room-temperature storage.

Cost: projected below existing vaccines.

IP: strong US–Japan patent estate supporting exclusivity.

Plan: US IND 2029 → PoC 2031; open to global partnering/out-licensing.

Platform extensions: (1) Oncology EV vaccine, (2) CNS-targeted nucleic-acid EV (DDS), (3) immune-tolerance EV; plus efficient protein loading and advanced CMC/QC markers for scalable, consistent development.

Stage

  • Planning

Type

  • Research
  • Technical
  • Financing

Organisation

EXORPHIA, INC.

Company (SME/startup) / 中小企業・スタートアップ

Tokyo, Japan